A study published in Nature Medicine looks at neutralisation of SARS-CoV-2 variants with key spike protein mutations by Pfizer/BioNTech COVID-19 vaccine-elicited sera.
Prof Jonathan Ball, Professor of Molecular Virology, University of Nottingham, said:
“This is important work and provides reassurance that the antibody response generated by the Pfizer vaccine is able to neutralise Sars2 coronavirus genetically engineered to carry some of the mutations seen in the variants of concern first identified in the UK and South Africa.
“However, we suspect that the effects of these mutations can be influenced by mutations occurring in other parts of the spike protein, so it will be important to validate these promising findings using viruses engineered to carry all of the mutations found in each variant.”
‘Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera’ by Xuping Xie et al was published in Nature Medicine on Monday 8 February
All our previous output on this subject can be seen at this weblink:
Prof Jonathan Ball: Receive UKRI funding to develop DNA-based Covid vaccines
None others received.